RebrAIn, SAS

Company profile

About RebrAIn, SAS

RebrAIn is a medical technology company specializing in precision brain targeting for functional neurosurgery, with a focus on deep brain stimulation (DBS) procedures for movement disorders. Founded as a spin-off of the University Hospital of Bordeaux and Inria after 10 years of academic research, the company was created by Professor Emmanuel Cuny, a neurosurgeon, and Professor Nejib Zemzemi, a researcher in applied mathematics at Inria. The company's flagship service is a supervised AI-driven solution that provides millimetric MRI-guided targeting for neurosurgical procedures. Using advanced algorithms and a health data exchange platform, RebrAIn identifies 18 anatomical landmarks per brain hemisphere to precisely locate treatment targets such as the subthalamic nucleus (STN) for Parkinson's Disease and the ventral intermediate nucleus (VIM) for Essential Tremor. The platform processes standard T1 MRI scans through a secure cloud-based system, delivering marked MRI images with target overlays within 24 hours. RebrAIn's technology aims to simplify and standardize neurosurgical procedures, potentially eliminating the need for intraoperative electrophysiology and enabling surgery under general anesthesia. This approach reduces procedure time, hospital stays, and patient trauma while maintaining high precision. The company serves neurosurgeons and hospital systems, with over 60 sites worldwide having adopted the technology and more than 1,000 targeting operations performed. RebrAIn operates with dual headquarters in France and the United States, positioning itself to serve both European and North American markets in the rapidly growing field of functional neurosurgery.

Company description · RebrAIn, SAS official website